N-alpha-acetyltransferase 60 (NAA60)

N-alpha-acetyltransferase 60 (NAA60), also known as NatF, is a member of the N-terminal acetyltransferase (NAT) family that catalyzes the transfer of an acetyl group from acetyl-coenzyme A to the N-terminus of proteins, with a particular preference for acetylating the cytosolic N-termini of transmembrane proteins[1][2][3][4][5]. This enzyme is distinct among NATs because it is localized primarily to the cytosolic face of the Golgi apparatus, where it binds directly to membranes through its C-terminal amphipathic helices[1][4]. NAA60's activity is important for processes including protein modification, chromatin assembly, and chromosome integrity, and it may also have minor or context-dependent histone acetyltransferase activity[3][5]. Genetic defects in NAA60 have been linked to idiopathic basal ganglia calcification[5]. No drugs are currently known to target NAA60, and there are no established biomarkers for its activity[5]. Inhibiting or disrupting NAA60 is expected to alter the acetylation of membrane proteins, potentially affecting protein stability, trafficking, and cellular homeostasis.

Other names

NatFHAT4NAT15UNQ2771/PRO7155hNaa60FLJ14154Histone acetyltransferase type B protein 4N-acetyltransferase 15N-alpha-acetyltransferase FIBGC9epididymis secretory sperm binding protein

Inhibition or modulation of NAA60 would presumably reduce or alter N-terminal acetylation of its substrates, affecting the function, stability, or localization of target proteins. Specific drug mechanisms are unknown due to limited drug development targeting this protein.